Celldex Therapeutics (CLDX) Competitors

Celldex Therapeutics (NASDAQ:CLDX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations.

Do institutionals and insiders believe in CLDX or IONS?

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 3.8% of Celldex Therapeutics shares are held by insiders. Comparatively, 2.6% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is CLDX or IONS more profitable?

Ionis Pharmaceuticals has a net margin of -64.25% compared to Celldex Therapeutics' net margin of -1,544.32%. Celldex Therapeutics' return on equity of -19.75% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	-1,544.32%	-19.75%	-18.86%
Ionis Pharmaceuticals	-64.25%	-100.05%	-15.70%

Which has more risk and volatility, CLDX or IONS?

Celldex Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.

Does the MarketBeat Community favor CLDX or IONS?

Ionis Pharmaceuticals received 81 more outperform votes than Celldex Therapeutics when rated by MarketBeat users. However, 75.27% of users gave Celldex Therapeutics an outperform vote while only 60.46% of users gave Ionis Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Celldex Therapeutics	Outperform Votes 627 75.27%	Underperform Votes 206 24.73%
Ionis Pharmaceuticals	Outperform Votes 708 60.46%	Underperform Votes 463 39.54%

Do analysts prefer CLDX or IONS?

Celldex Therapeutics currently has a consensus target price of $53.90, indicating a potential upside of 166.24%. Ionis Pharmaceuticals has a consensus target price of $56.67, indicating a potential upside of 72.56%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Celldex Therapeutics is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90
Ionis Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65

Which has preferable earnings and valuation, CLDX or IONS?

Celldex Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$7.56M	177.79	-$141.43M	-$2.70	-7.50
Ionis Pharmaceuticals	$717.25M	7.29	-$366.29M	-$2.99	-10.98

Does the media favor CLDX or IONS?

In the previous week, Celldex Therapeutics and Celldex Therapeutics both had 12 articles in the media. Celldex Therapeutics' average media sentiment score of 1.66 beat Ionis Pharmaceuticals' score of 1.12 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ionis Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celldex Therapeutics beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.